Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
25 Março 2024 - 9:15AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four
presentations at the American College of Cardiology 73rd Annual
Scientific Session (ACC.24) taking place in Atlanta, GA from April
6, 2024 – April 8, 2024.
Title: 1075-11 - Efficacy and Safety of
Aficamten in the First Cohort of Patients with Symptomatic
Obstructive Hypertrophic Cardiomyopathy Completing 1-Year
Follow-Up: Findings From the FOREST-HCM
StudyPresenter: Sara Saberi, M.D., M.S., Associate
Professor of Internal Medicine, University of Michigan Health
Frankel Cardiovascular CenterSession: 1075 -
Bulking Up: Advances in Hypertrophic
CardiomyopathyDate: April 7,
2024Presentation Time: 2:00 PM-2:10 PM Eastern
Time Location: Moderated Poster Theater 03
Title: 1226-128 - Association Between Beta
Blocker Use and Incidence of New Atrial Fibrillation and Flutter
Post-Septal Myectomy for Obstructive Hypertrophic
CardiomyopathyPresenter: Morris M. Kim, M.D.,
Cardiovascular Disease Fellow, Oregon Health & Science
UniversitySession: 1226 - Heart Failure and
Cardiomyopathies: Special Populations 02Date:
April 6, 2024Presentation Time: 10:45 AM-11:30 AM
Eastern Time Location: Hall B4-5
Title: 1343-122 - Standard of Care Medication
Patterns of Use Before and After Septal Myectomy in Patients with
Obstructive Hypertrophic CardiomyopathyPresenter:
Tristan B. Post, M.D., Clinical Research Coordinator, Oregon Health
& Science UniversitySession: 1343 - Heart
Failure and Cardiomyopathies: Pharmacology 08Date:
April 7, 2024Presentation Time: 9:15 AM-10:00 AM
Eastern Time Location: Hall B4-5
Title: 1075-03 - Racial and Ethnic Differences
in Cardiovascular Outcomes in Patients Diagnosed with Hypertrophic
CardiomyopathyPresenter: Nosheen Reza, M.D.,
Assistant Professor of Medicine, Perelman School of Medicine at the
University of PennsylvaniaSession: 1075 - Bulking
Up: Advances in Hypertrophic CardiomyopathyDate:
April 7, 2024Presentation Time: 1:00 PM-1:10 PM
Eastern Time Location: Moderated Poster Theater
03
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in two
ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as
monotherapy compared to metoprolol as monotherapy in patients with
obstructive HCM and ACACIA-HCM, evaluating aficamten in patients
with non-obstructive HCM. Cytokinetics is also developing omecamtiv
mecarbil, a cardiac muscle activator, in patients with heart
failure. Additionally, Cytokinetics is developing CK-586, a cardiac
myosin inhibitor with a mechanism of action distinct from aficamten
for the potential treatment of HFpEF, and CK-136, a cardiac
troponin activator for the potential treatment HFrEF and other
types of heart failure, such as right ventricular failure resulting
from impaired cardiac contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice President,
Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024